Navigation Links
Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at CTOS Annual Meeting
Date:11/6/2009

CALGARY, Nov. 6 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX:ONC, NASDAQ:ONCY) ("Oncolytics" or the "Company") today announced updated results from a Phase II study of intravenous REOLYSIN(R) in patients with sarcomas metastatic to the lung in a poster presentation at the 15th Annual Connective Tissue Oncology Society Meeting held in Miami Beach, Florida, from November 5th to 7th. The poster presentation, entitled "A Phase II Study of Intravenous REOLYSIN (Wild-type Reovirus) in the Treatment of Patients with Bone and Soft Tissue Sarcomas Metastatic to the Lung", was delivered by Dr. Kamalesh Sankhala, part of principal investigator Dr. Monica Mita's team at the Institute of Drug Development (IDD), the Cancer Therapy and Research Center at the University of Texas Health Science Center, (UTHSC), San Antonio, Texas.

The investigators reported that the treatment has been well tolerated to date, and that 19 of 44 evaluable patients experienced stable disease ranging from two to 20 months, resulting in a total clinical benefit rate (complete response + partial response + stable disease) of 43%. The response objective for the study was three or more patients having prolonged stabilization of disease (greater than 6 months) or better, for the agent to be considered. The trial exceeded its established objective with six patients experiencing stable disease for more than six months. Two patients have experienced stable disease for more than 19 months. One has synovial cell sarcoma that relapsed following surgery, while the other has Ewing's Sarcoma and had previously progressed following multiple treatments.

"We were very happy to participate in the study," said Dr. Mita. "REOLYSIN is a promising option for patients with sarcoma as shown by the results of this study. As a single agent the virus had a clinical benefit rate of 43% and it was very well tolerated. Further studies combining REOLYSIN with chemotherapy are contempl
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
2. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
5. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
6. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
7. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
10. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
11. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... October 29, 2014 Global polyvinyl chloride ... world economic crisis during 2008-2009, especially in North America ... and currently is keeping to a growing trend. , ... is utilized in the construction segment. In 2013, the ... profiles, tubing, sheets and rigid film. Moreover, the PVC ...
(Date:10/30/2014)... 30, 2014 James Sherley says he has ... tissue stem cell technology since his days as a principal ... in the late 1990’s. Sherley founded the ASCTC as ... holds all the intellectual property developed in Sherley’s research over ... Massachusetts Institute of Technology (MIT), and more recently as a ...
(Date:10/30/2014)... CARLSBAD, Calif. , Oct. 30, 2014 Isis ... antisense therapeutics, today announced that management will present a company ... 2014 at 8:30 a.m. ET in Boston, MA. ... will be available on the "Investors & Media" section of ... available on the Isis website within 48 hours and will ...
(Date:10/27/2014)... Ryan Carfley , Managing Partner at ... down with Bryan Hamilton, the publisher of the Triangle Business ... in the Research Triangle region of North Carolina. , Just ... the roundtable include the role of social media in ... balance and the unique role that Millennials play in the ...
Breaking Biology Technology:Global Polyvinyl Chloride Demand Is on Upward Trend Now, Says Merchant Research & Consulting in Its Topical Study 2Global Polyvinyl Chloride Demand Is on Upward Trend Now, Says Merchant Research & Consulting in Its Topical Study 3Boston’s Adult Stem Cell Technology Center, LLC Introduces A New Technology for Monitoring Previously Elusive Adult Stem Cells 2Boston’s Adult Stem Cell Technology Center, LLC Introduces A New Technology for Monitoring Previously Elusive Adult Stem Cells 3Boston’s Adult Stem Cell Technology Center, LLC Introduces A New Technology for Monitoring Previously Elusive Adult Stem Cells 4Isis Pharmaceuticals to Present at the Nomura Biotechnology Conference 2Personify's Ryan Carfley Talks Recruiting with Triangle Business Journal, RPG Solutions 2Personify's Ryan Carfley Talks Recruiting with Triangle Business Journal, RPG Solutions 3
... , ... transfer has traditionally been a fast but inefficient method , ... buffer system, transfer efficiency can be greatly increased. In protein , ... elution of the proteins , from a gel and ...
... Introduction , Amplification of ... highly sensitive method capable of copying millions of DNA molecules from , ... extreme sensitivity of this method, , any carry-over ... or extra bands. Carry-over contamination can be avoided by using positive , ...
... Luis A Ugozzoli, Bio-Rad Laboratories, Inc., 2000 Alfred Nobel Drive,Hercules, ... Introduction , ... greatly refined since its advent 16 years ago. Several improvements , ... the way PCR is performed today relative to earlier protocols. ...
Cached Biology Technology:Increased Transfer Efficiency Using a Discontinuous Buffer System With the Trans-Blot SD Cell 2Increased Transfer Efficiency Using a Discontinuous Buffer System With the Trans-Blot SD Cell 3Increased Transfer Efficiency Using a Discontinuous Buffer System With the Trans-Blot SD Cell 4Inactivation of Contaminating Templates in PCR Using High Intensity Ultraviolet Light 2Inactivation of Contaminating Templates in PCR Using High Intensity Ultraviolet Light 3The Gradient Feature: Use in Optimization of Allelic Discrimination Assays, Rev B 2The Gradient Feature: Use in Optimization of Allelic Discrimination Assays, Rev B 3The Gradient Feature: Use in Optimization of Allelic Discrimination Assays, Rev B 4The Gradient Feature: Use in Optimization of Allelic Discrimination Assays, Rev B 5The Gradient Feature: Use in Optimization of Allelic Discrimination Assays, Rev B 6The Gradient Feature: Use in Optimization of Allelic Discrimination Assays, Rev B 7The Gradient Feature: Use in Optimization of Allelic Discrimination Assays, Rev B 8
(Date:10/30/2014)... When most animals begin life, cells immediately begin accepting ... organ. However, mammals, including humans, are special. The cells ... choice – to become the protective placenta or to ... critical first step that research from Michigan State University ... current issue of PLOS Genetics , ...
(Date:10/30/2014)... 2014 – Bacteria in the gastrointestinal tract fulfill ... Yet, these same bacteria can induce strong inflammatory ... the gut and enter the bloodstream. , Although ... the body, chronic or systemic inflammation is linked ... established the involvement of inflammatory processes in the ...
(Date:10/30/2014)... , Oct. 29, 2014  Securus Technologies, ... justice technology solutions for public safety, investigation, ... has deployed exciting enhancements to its THREADS™ ... to provide actionable intelligence and focused leads ... to drive technological innovation through identifying and ...
Breaking Biology News(10 mins):Identifying the source of stem cells 2Breakdown in gut barriers to bacteria may promote inflammation and craving in alcoholics 2Securus Technologies Adds Advanced Features to Its Industry-Leading Investigative Analytics Product 2
... at the Texas Biomedical Research Institute in San Antonio ... of "bad" cholesterol. This discovery could lead to the ... heart disease., "Our findings are important because they provide ... reduce heart disease risk in humans," said Laura Cox, ...
... Dr. Philippe Wernet, chemist Prof. Dr. Athina Zouni of Humboldt ... Accelerator Laboratory and Dr. Junko Yano of the Lawrence Berkeley ... In spite of the fact that all aerobic organisms ... Because as part of photosynthesis, green plants, algae, and cyanobacteria ...
... predicts their political opinions on economic redistribution, according ... , a journal of the Association for Psychological ... psychological scientists Michael Bang Petersen of Aarhus ... Santa Barbara believe that the link may ...
Cached Biology News:4 genes indentified that influence levels of 'bad' cholesterol 2Snap shots of 1 of life's central processes 2Political motivations may have evolutionary links to physical strength 2
... [RS17 ] to PRKAR2 cAMP is ... of cellular functions. cAMP exerts its effects ... which transduces the signal through phosphorylation of ... AMPK is a tetramer composed of two ...
... Rocking Shaker provides the exact agitation ... The very slow to fast speed ... provide a gentle wave motion that ... blotted membranes to achieve faster, more ...
...
... Have you bought a Perkin Elmer UltraVIEW ... using the Andor iXon and iQ software? No ... that upgrade. You keep your existing microscope, lasers, ... will customise it to work with our precision ...
Biology Products: